1-甲基-2-(甲硫基)-4,5-二氢-1h-咪唑氢碘化物 | 61076-89-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 中文名称: 1-甲基-2-(甲硫基)-4,5-二氢-1h-咪唑氢碘化物
• 英文名称: 1-methyl-2-(methylthio)-2-imidazoline hydroiodide
• 英文别名: 1-methyl-2-methylthio-2-imidazoline hydroiodide；1-methyl-2-methylthio-2-imidazolinium iodide；1-methyl-2-methylsulfanyl-4,5-dihydro-1H-imidazole; hydriodide；1-Methyl-2-methylmercapto-4,5-dihydro-1H-imidazol; Hydrojodid；1-methyl-2-(methylthio)-4,5-dihydro-1H-imidazole hydroiodide；1-methyl-2-methylmercapto-2-imidazoline.hydroiodide；3-methyl-2-methylsulfanyl-4,5-dihydro-1H-imidazol-3-ium;iodide
• CAS: 61076-89-9
• 化学式: C₅H₁₀N₂S*HI
• 分子量: 258.126
• InChiKey: GBQRICLUHNYAPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.27
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  40.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933290090

反应信息

• 作为反应物：
  描述：

  1-甲基-2-(甲硫基)-4,5-二氢-1h-咪唑氢碘化物 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 4.0h， 以90%的产率得到(1-methyl-4,5-dihydro-1H-imidazol-2-yl)-hydrazine hydroiodide
  参考文献：
  名称：

  Synthesis and Quantitative Structure−Activity Relationships of 17β-(Hydrazonomethyl)-5β-androstane-3β,14β-diol Derivatives That Bind to Na⁺,K⁺-ATPase Receptor

  摘要：

  A series of 17 beta-(hydrazonomethyl)-5 beta-androstane-3 beta,14 beta-diol derivatives was synthesized and evaluated in the displacement of [H-3]ouabain binding from Na+,K+-ATPase. The data were explored with multiple linear regression and partial least-squares to find possible quantitatives structure-activity relationships. Good correlations were found between binding to the receptor and van der Waals volumes or molar refractivities of the 17 beta-hydrazonomethyl substituents and pK(a) values of the compounds. Equivalent results were obtained using the proton affinity (calculated using MOPAC) of the hydrazone residues instead of experimental pK(a). As basicity or related electronic factors of the substituents explain a significant portion of the observed changes in the activity, an ion-pair interaction between a carboxylate residue of the enzyme and the protonated 17 beta-hydrazonomethyl group, as postulated by Thomas, plays an important role in the interaction of the ligand to the Na+,K+-ATPase receptor.

  DOI：

  10.1021/jm950806n
• 作为产物：
  描述：

  2-巯基-1-甲基咪唑(甲硫咪唑) 、 碘甲烷 以 丙酮 为溶剂， 反应 4.0h， 以to give 1-methyl-2-(methylthio)-4,5-dihydro-1H-imidazole hydroiodide (8.79 g, 77%) as beige solid的产率得到1-甲基-2-(甲硫基)-4,5-二氢-1h-咪唑氢碘化物
  参考文献：
  名称：

  Hepatitis C Virus Inhibitors

  摘要：

  本公开涉及化合物、组合物和方法，用于治疗丙型肝炎病毒（HCV）感染。还公开了含有这些化合物的制药组合物以及使用这些化合物治疗HCV感染的方法。

  公开号：

  US20140017195A1

文献信息

• Synthesis and evaluation of guanidinyl pyrrolidines as bifunctional catalysts for enantioselective conjugate additions to cyclic enones
  作者：Sunil V. Pansare、Rajinikanth Lingampally

  DOI：10.1039/b812038b

  日期：——

  Guanidinyl pyrrolidines derived from ‘S’-proline are effective catalysts for the enantioselective conjugate addition of malonate, nitroalkane and other carbon and heteroatom nucleophiles to cyclohexenone and cyclopentenone in the absence of basic additives. The stereoselectivity is strongly dependant on catalyst loading as well as reaction concentration.

  衍生自“ S ”-脯氨酸的胍基吡咯烷是将丙二酸酯，硝基烷和其他碳原子和杂原子亲核试剂对映选择性共轭加成的有效催化剂。环己烯酮 和 环戊烯酮在没有碱性添加剂的情况下。立体选择性很大程度上取决于催化剂的负载以及反应浓度。
• [EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2009102318A1

  公开（公告）日：2009-08-20

  The present disclosure relates to (4-4' -diimidazolyl) biphenyls compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

  本公开涉及（4-4'-二咪唑基）联苯类化合物及用于治疗丙型肝炎病毒（HCV）感染的方法。还公开了含有这些化合物的药物组合物以及在治疗HCV感染中使用这些化合物的方法。
• Hydrazono-5.beta., 14.beta.-androstane derivatives active on the
  申请人：SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.

  公开号：US05538960A1

  公开（公告）日：1996-07-23

  The present invention relates to new 17-hydrazonomethyl- and 17-hydrazono-14.beta.-hydroxy-5.beta.-androstane derivatives active on the cardiovascular system, to a process for their preparation and to pharmaceutical compositions containing same for the treatment of cardiovascular disorders, such as heart failure and hypertension.

  本发明涉及对心血管系统活性的新17-酰肼甲基和17-酰肼基-14-β-羟基-5-β-雄烷衍生物，以及它们的制备方法和含有相同物质的用于治疗心血管疾病，如心力衰竭和高血压的药物组合物。
• 17-(3-imino-2-alkylpropenyl)-5.beta., 14.beta.-androstane derivatives
  申请人：Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.

  公开号：US05705662A1

  公开（公告）日：1998-01-06

  New 17-\x9b3-imino-2-alkyl propenyl!-14.beta.-hydroxy-5.beta.-androstane derivatives active on the cardiovascular system by inhibiting Na+,K+-ATPase, a process for their preparation, and to pharmaceutical compositions for the treatment of cardiovascular disorders, such as heart failure and hypertension.

  新的17-乙基亚氨基-2-烯丙基-14-β-羟基-5-β-雄烷衍生物对心血管系统具有活性，通过抑制Na+，K+-ATPase，制备这些衍生物的方法，以及用于治疗心血管疾病（如心力衰竭和高血压）的药物组合物。
• Synthesis and carbonic anhydrase activating properties of a series of 2-amino-imidazolines structurally related to clonidine¹
  作者：Niccolò Chiaramonte、Soumia Maach、Caterina Biliotti、Andrea Angeli、Gianluca Bartolucci、Laura Braconi、Silvia Dei、Elisabetta Teodori、Claudiu T. Supuran、Maria Novella Romanelli

  DOI：10.1080/14756366.2020.1749602

  日期：2020.1.1

  for a long time. This compound has been extensively modified but only in few instances the imidazole ring has been replaced with other heterocycles. It was envisaged that the imidazoline ring could be a bioisoster of the imidazole moiety. Indeed, we report that clonidine, a 2-aminoimidazoline derivative, was found able to activate several human CA isoforms (hCA I, IV, VA, VII, IX, XII and XIII), with

  组胺的碳酸酐酶（CA，EC 4.2.1.1）活化特性早已为人所知。该化合物已被广泛修饰，但仅在少数情况下，咪唑环已被其他杂环取代。设想咪唑啉环可以是咪唑部分的生物等排体。确实，我们报道了可乐定是一种2-氨基咪唑啉衍生物，被发现能够激活几种人类CA亚型（hCA I，IV，VA，VII，IX，XII和XIII），其效力在微摩尔范围内，而无活性在hCA II上。然后合成了一系列与可乐定有关的2-氨基咪唑啉，并在选定的hCA亚型上进行了测试。这些化合物对hCA II无活性，同时在hCA I，VA，VII和XIII上显示出活化特性，KA值在微摩尔范围内。